Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 5.04
ACRX's Cash to Debt is ranked higher than
56% of the 315 Companies
in the Global Medical Devices industry.

( Industry Median: 2.75 vs. ACRX: 5.04 )
Ranked among companies with meaningful Cash to Debt only.
ACRX' s Cash to Debt Range Over the Past 10 Years
Min: 0.31  Med: 3.52 Max: N/A
Current: 5.04
Equity to Asset 0.30
ACRX's Equity to Asset is ranked lower than
88% of the 293 Companies
in the Global Medical Devices industry.

( Industry Median: 0.65 vs. ACRX: 0.30 )
Ranked among companies with meaningful Equity to Asset only.
ACRX' s Equity to Asset Range Over the Past 10 Years
Min: -0.01  Med: 0.53 Max: 0.69
Current: 0.3
-0.01
0.69
F-Score: 1
Z-Score: -0.41
M-Score: -2.87
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -136.25
ACRX's Operating margin (%) is ranked lower than
82% of the 301 Companies
in the Global Medical Devices industry.

( Industry Median: 2.36 vs. ACRX: -136.25 )
Ranked among companies with meaningful Operating margin (%) only.
ACRX' s Operating margin (%) Range Over the Past 10 Years
Min: -1805.22  Med: -981.40 Max: -22.6
Current: -136.25
-1805.22
-22.6
Net-margin (%) -155.81
ACRX's Net-margin (%) is ranked lower than
81% of the 301 Companies
in the Global Medical Devices industry.

( Industry Median: 1.62 vs. ACRX: -155.81 )
Ranked among companies with meaningful Net-margin (%) only.
ACRX' s Net-margin (%) Range Over the Past 10 Years
Min: -1875.09  Med: -1016.46 Max: -79.4
Current: -155.81
-1875.09
-79.4
ROE (%) -62.84
ACRX's ROE (%) is ranked lower than
82% of the 287 Companies
in the Global Medical Devices industry.

( Industry Median: 2.51 vs. ACRX: -62.84 )
Ranked among companies with meaningful ROE (%) only.
ACRX' s ROE (%) Range Over the Past 10 Years
Min: -130.03  Med: -55.67 Max: -43.78
Current: -62.84
-130.03
-43.78
ROA (%) -30.50
ACRX's ROA (%) is ranked lower than
73% of the 316 Companies
in the Global Medical Devices industry.

( Industry Median: 0.42 vs. ACRX: -30.50 )
Ranked among companies with meaningful ROA (%) only.
ACRX' s ROA (%) Range Over the Past 10 Years
Min: -134.55  Med: -73.84 Max: -26.84
Current: -30.5
-134.55
-26.84
ROC (Joel Greenblatt) (%) -202.73
ACRX's ROC (Joel Greenblatt) (%) is ranked lower than
75% of the 313 Companies
in the Global Medical Devices industry.

( Industry Median: 3.95 vs. ACRX: -202.73 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ACRX' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -2973.59  Med: -907.22 Max: -173.98
Current: -202.73
-2973.59
-173.98
Revenue Growth (3Y)(%) 26.00
ACRX's Revenue Growth (3Y)(%) is ranked higher than
95% of the 208 Companies
in the Global Medical Devices industry.

( Industry Median: 3.60 vs. ACRX: 26.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ACRX' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 26
Current: 26
0
26
EBITDA Growth (3Y)(%) -12.50
ACRX's EBITDA Growth (3Y)(%) is ranked lower than
73% of the 182 Companies
in the Global Medical Devices industry.

( Industry Median: 2.90 vs. ACRX: -12.50 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ACRX' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -72.35 Max: -12.5
Current: -12.5
EPS Growth (3Y)(%) -12.80
ACRX's EPS Growth (3Y)(%) is ranked lower than
70% of the 186 Companies
in the Global Medical Devices industry.

( Industry Median: 2.90 vs. ACRX: -12.80 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ACRX' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -67.45 Max: -12.8
Current: -12.8
» ACRX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2014

ACRX Guru Trades in Q4 2014

Paul Tudor Jones Sold Out
» More
Q1 2015

ACRX Guru Trades in Q1 2015

Paul Tudor Jones 52,600 sh (New)
» More
Q2 2015

ACRX Guru Trades in Q2 2015

Paul Tudor Jones 24,100 sh (-54.18%)
» More
Q3 2015

ACRX Guru Trades in Q3 2015

Paul Tudor Jones Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with ACRX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 3.91
ACRX's P/B is ranked lower than
73% of the 382 Companies
in the Global Medical Devices industry.

( Industry Median: 2.58 vs. ACRX: 3.91 )
Ranked among companies with meaningful P/B only.
ACRX' s P/B Range Over the Past 10 Years
Min: 2.16  Med: 6.01 Max: 78
Current: 3.91
2.16
78
P/S 8.80
ACRX's P/S is ranked lower than
99.99% of the 382 Companies
in the Global Medical Devices industry.

( Industry Median: 2.33 vs. ACRX: 8.80 )
Ranked among companies with meaningful P/S only.
ACRX' s P/S Range Over the Past 10 Years
Min: 7.21  Med: 40.60 Max: 163
Current: 8.8
7.21
163
Current Ratio 15.55
ACRX's Current Ratio is ranked higher than
96% of the 314 Companies
in the Global Medical Devices industry.

( Industry Median: 2.82 vs. ACRX: 15.55 )
Ranked among companies with meaningful Current Ratio only.
ACRX' s Current Ratio Range Over the Past 10 Years
Min: 0.43  Med: 4.59 Max: 20.39
Current: 15.55
0.43
20.39
Quick Ratio 15.55
ACRX's Quick Ratio is ranked higher than
96% of the 314 Companies
in the Global Medical Devices industry.

( Industry Median: 2.04 vs. ACRX: 15.55 )
Ranked among companies with meaningful Quick Ratio only.
ACRX' s Quick Ratio Range Over the Past 10 Years
Min: 0.43  Med: 4.59 Max: 20.39
Current: 15.55
0.43
20.39
Days Sales Outstanding 357.13
ACRX's Days Sales Outstanding is ranked lower than
98% of the 264 Companies
in the Global Medical Devices industry.

( Industry Median: 69.24 vs. ACRX: 357.13 )
Ranked among companies with meaningful Days Sales Outstanding only.
ACRX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 0
Current: 357.13

Valuation & Return

vs
industry
vs
history
Price/Net Cash 12.14
ACRX's Price/Net Cash is ranked higher than
52% of the 146 Companies
in the Global Medical Devices industry.

( Industry Median: 12.77 vs. ACRX: 12.14 )
Ranked among companies with meaningful Price/Net Cash only.
ACRX' s Price/Net Cash Range Over the Past 10 Years
Min: 2.2  Med: 8.31 Max: 25
Current: 12.14
2.2
25
Price/Net Current Asset Value 5.03
ACRX's Price/Net Current Asset Value is ranked higher than
59% of the 293 Companies
in the Global Medical Devices industry.

( Industry Median: 6.17 vs. ACRX: 5.03 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
ACRX' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 2.14  Med: 7.60 Max: 927
Current: 5.03
2.14
927
Price/Tangible Book 3.91
ACRX's Price/Tangible Book is ranked higher than
55% of the 378 Companies
in the Global Medical Devices industry.

( Industry Median: 4.30 vs. ACRX: 3.91 )
Ranked among companies with meaningful Price/Tangible Book only.
ACRX' s Price/Tangible Book Range Over the Past 10 Years
Min: 2.08  Med: 5.94 Max: 57.94
Current: 3.91
2.08
57.94
Price/Median PS Value 0.22
ACRX's Price/Median PS Value is ranked higher than
96% of the 384 Companies
in the Global Medical Devices industry.

( Industry Median: 1.00 vs. ACRX: 0.22 )
Ranked among companies with meaningful Price/Median PS Value only.
ACRX' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.18  Med: 0.95 Max: 3.96
Current: 0.22
0.18
3.96
Earnings Yield (Greenblatt) (%) -32.29
ACRX's Earnings Yield (Greenblatt) (%) is ranked lower than
90% of the 304 Companies
in the Global Medical Devices industry.

( Industry Median: 0.90 vs. ACRX: -32.29 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ACRX' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -32.29  Med: 3.75 Max: 9.1
Current: -32.29
-32.29
9.1

More Statistics

Revenue(Mil) $18
EPS $ -0.68
Beta2.90
Short Percentage of Float14.04%
52-Week Range $2.59 - 9.32
Shares Outstanding(Mil)44.45

Analyst Estimate

Dec15 Dec16 Dec17 Dec18
Revenue(Mil) 20 12 15 55
EPS($) -0.50 -0.73 -0.60 -0.14
EPS without NRI($) -0.50 -0.73 -0.60 -0.14

Business Description

Industry: Medical Devices » Medical Devices
Compare: » details
Traded in other countries:R5X.Germany,
AcelRx Pharmaceuticals Inc was was incorporated in Delaware on July 13, 2005 as SuRx, Inc. In January 2006, the Company has changed its name to AcelRx Pharmaceuticals, Inc. It is a development stage company. The Company is a specialty pharmaceutical company engaged in the development and commercialization of therapies for the treatment of acute and breakthrough pain. The Company's main product candidate, Zalviso, formerly known as the Sufentanil NanoTab PCA System, or ARX-01, is currently under review by the FDA for marketing approval, and is designed to improve the management of moderate-to-severe acute pain in patients in the hospital setting. In addition, in December 2013, the Company entered into a collaboration agreement with Grünenthal for the commercialization of Zalviso in Europe and Australia. Its sufentanil-based products are subject to extensive regulation by the DEA, due to their status as scheduled drugs. Its registered trademarks include ACELRX and NANOTAB.
» More Articles for ACRX

Headlines

Articles On GuruFocus.com
Weekly CFO Buys Highlight: BK, MWW, BLD, ACRX, PSEC Sep 12 2011 

More From Other Websites
AcelRx Pharmaceuticals to Present at Two Upcoming Investor Events in February Feb 03 2016
AcelRx Pharmaceuticals Announces Presentation of Phase 3 Sufentanil Sublingual 30 mcg Tablet... Jan 21 2016
AcelRx Pharmaceuticals Announces Presentation of Phase 3 Sufentanil Sublingual 30 mcg Tablet... Jan 21 2016
ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition,... Jan 11 2016
AcelRx Pharmaceuticals Announces Anticipated 2016 Milestones Jan 10 2016
AcelRx Pharmaceuticals Announces Anticipated 2016 Milestones Jan 10 2016
AcelRx Completes Protocol Review with FDA and Plans to Initiate Phase 3 Open-Label Study (IAP312)... Jan 08 2016
ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jan 08 2016
AcelRx Completes Protocol Review with FDA and Plans to Initiate Phase 3 Open-Label Study (IAP312)... Jan 08 2016
AcelRx Pharmaceuticals Receives Notice of Eligibility for Centralized Review of ARX-04 from European... Dec 23 2015
AcelRx Pharmaceuticals Receives Notice of Eligibility for Centralized Review of ARX-04 from European... Dec 23 2015
AcelRx Tanks on Pre-NDA Results Dec 14 2015
AcelRx Pharmaceuticals Conducts Pre-NDA Meeting with U.S. Food and Drug Administration for ARX-04 Dec 14 2015
ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Dec 14 2015
AcelRx Pharmaceuticals Conducts Pre-NDA Meeting with U.S. Food and Drug Administration for ARX-04 Dec 14 2015
ACELRX PHARMACEUTICALS INC Financials Dec 08 2015
Should You Avoid AcelRx Pharmaceuticals Inc (ACRX)? Dec 08 2015
AcelRx Pharmaceuticals to Present at Piper Jaffray 27th Annual Healthcare Conference Nov 23 2015
A Look at Equity Market Momentum - Research on Multi-Fineline Electronix, AcelRx Pharmaceuticals,... Nov 19 2015
AcelRx Pharmaceuticals Announces Sublingual Sufentanil Data Presentation at the American Society of... Nov 19 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK